Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tango Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Tango Therapeutics, Inc.

TNGX

Tango Therapeutics, Inc.

About Tango Therapeutics, Inc.

Tango Therapeutics is a precision oncology company focused on developing targeted cancer therapies by exploiting genetic vulnerabilities such as tumor suppressor gene loss. Its pipeline includes novel small molecules targeting PRMT5 and CoREST, aimed at genetically defined patient populations. The company leverages advanced target discovery platforms, collaborates with industry partners, and relies on third-party manufacturing to deliver innovative treatments for cancers with high unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tango Therapeutics, Inc.

1
1
Tango Therapeutics, Inc. Tango Therapeutics Reports $45.5 Million Net Loss in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Tango Therapeutics, Inc. Tango Therapeutics Reports $62.4 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Tango Therapeutics, Inc. Tango Therapeutics Reports $53.8M Collaboration Revenue and $15.9M Net Income in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tango Therapeutics, Inc. Tango Therapeutics Reports 84% Revenue Decline and $38.9 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tango Therapeutics, Inc. Tango Therapeutics Reports Q1 2025 Financial Results with $39.9M Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tango Therapeutics, Inc. Tango Therapeutics Reports $130.3 Million Net Loss and $42.1 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Tango Therapeutics, Inc. Tango Therapeutics Reports Revenue Growth, Increased Expenses, and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments